These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 1327312)

  • 1. Low molecular weight heparins. An objective overview.
    Hoppensteadt D; Walenga JM; Fareed J
    Drugs Aging; 1992; 2(5):406-22. PubMed ID: 1327312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effects.
    Fareed J; Walenga JM; Lassen M; Borris L; Hoppensteadt D; Murphy R; Ahsan A; Weber S; Jorgensen LN; Hauch O
    Acta Chir Scand Suppl; 1990; 556():75-90. PubMed ID: 1963021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin).
    Fareed J; Walenga JM; Hoppensteadt D; Borris LC; Lassen MR
    Semin Thromb Hemost; 1991; 17 Suppl 3():319-28. PubMed ID: 1661440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin.
    Wolf H
    Med Clin North Am; 1994 May; 78(3):733-43. PubMed ID: 8170267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
    Harenberg J
    Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical studies on a low molecular weight heparin.
    Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
    Thromb Res; 1996; 81(2 Suppl):S1-27. PubMed ID: 8822124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
    Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
    Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
    Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
    Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin: a critical analysis of clinical trials.
    Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW
    Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Crowther M; Hirsh J
    Semin Thromb Hemost; 1997; 23(1):77-81. PubMed ID: 9156414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Hirsh J; Crowther M
    Thromb Haemost; 1997 Jul; 78(1):689-92. PubMed ID: 9198240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
    Ornstein DL; Hong-Dice YG; Papini JR
    Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of thromboembolism with various low-molecular-weight heparins.
    Haas S; Blümel G
    Haemostasis; 1988; 18 Suppl 3():82-7. PubMed ID: 2840379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.
    Heaton D; Pearce M
    Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of low molecular weight heparins and heparinoids: basic and clinical aspects.
    Hirsh J
    Aust N Z J Med; 1992 Oct; 22(5):487-95. PubMed ID: 1280097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.